CRISPR base editing for tailored tumour detection - 16/07/2026

Targeted genetic manipulation of signal transduction pathways in CAR T cells enhances anti-tumour potency

Chimeric antigen receptor (CAR) T cell therapy has emerged as a highly promising treatment modality but has so far been used almost exclusively for advanced haematologic malignancies. Researchers at the iFIT cluster of excellence in Tübingen have now used CRISPR base-editing technology to introduce precise point mutations into key signalling pathways of CAR T cells, significantly enhancing their long-term persistence and anti-tumour potency.

With the aid of physical forces it is possible to actively steer the formation of engineered tissue. For example, sound waves can be used to create functional vascular networks with blood vessel-like structures in vitro. Scientists at the Center for Molecular Biology of Heidelberg University have demonstrated this through their methodology for acoustic manipulation.

The University of Hohenheim becomes a European University through the EuroLeague of Life Sciences Universities. For ELLS, which is celebrating its 25th anniversary this year, this marks the beginning of a new chapter. The decision will provide students, researchers and staff at the University of Hohenheim in Stuttgart with increased opportunities to study, work and collaborate with partner universities across Europe.

The Friends of the German Cancer Research Center (DKFZ) support the DKFZ and aim to help strengthen its position in the international arena. With the DKFZ Innovation Award, presented at this year’s annual reception, the association honors Helmut Salih, a researcher whose innovative work bridges the gap between immunological research and patient care.

The University of Freiburg is strengthening its European collaboration in the field of Artificial Intelligence by having been accepted into the Virtual Centre of Excellence of the European AI initiative ELIAS. The Freiburg researchers contribute their expertise to the European network in areas including machine learning, computer vision, robot learning, automated reasoning, intelligent systems and neurotechnologies, as well as responsible AI.

Robots that can learn and adapt require not only data, AI tools, and algorithms but also direct communication with their users. Jens Kober would like to improve this interaction and as the new head of a research team at Fraunhofer IPA, he is focusing in particular on construction robotics.

In people with severely compromised immune systems, the JC polyomavirus can trigger a currently untreatable, usually fatal brain disease. Now, an international research team looking at the viral capsid has identified binding sites for neutralizing antibodies; these sites could be used to halt infection with JC polyomaviruses.

Prime Vector Technologies GmbH (PVT), a clinical-stage biotechnology company focusing on the development of viral vector-based vaccines, today announced that it has entered into an agreement with Boehringer Ingelheim for the assignment of certain patents and the exclusive licensing of its Orf virus (ORFV) platform for the development of next-generation cancer vaccines.

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve access to specialized and personalized cancer care.

A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center, Mannheim University Medical Center, Heidelberg University Hospital, and numerous partner institutions* have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic mutation in these tumors.

Researchers at the German Cancer Research Center (DKFZ) have identified a previously unknown key mechanism by which cancer cells suppress the immune system and thus evade the effects of immunotherapies. At the same time, the new study in mouse models and human tumor samples points to a promising way to prevent resistance to immunotherapy.

Primary CNS lymphomas in immunocompromised patients are among the rarest and at the same time most aggressive cancers – yet evidence-based recommendations for their diagnosis and treatment have been lacking. An international research team led by the Heidelberg Faculty of Medicine at Heidelberg University and the German Cancer Research Center has now identified characteristic imaging features of these tumors and developed a prognostic model.

An environmental bacterium could protect against the effects of stress right through to the next generation. Evidence of this emerged in a study using a mouse model carried out by researchers from Ulm and Frankfurt, the results of which were published in the journal `Molecular Psychiatry´. According to the study, the offspring of treated mothers were better protected against the effects of stress in adulthood than control animals.

The European Union is funding the PALACROS project with nearly €10 million under its “Horizon Europe” research programme. Researchers from Heidelberg University Hospital and Heidelberg University are helping shape the European PALACROS consortium, developing new standards for the treatment of locally advanced pancreatic cancer.

Effective July 1, the Hahn-Schickard Association for Applied Research e.V. will spin off its operational business and transfer it to the newly founded Hahn-Schickard gGmbH. This nonprofit company has assumed the universal legal succession of the association and has been entered in the commercial register of the Stuttgart District Court. It is legally represented by its managing director, Dr. Karl-Peter Fritz.

Through its “Proof of Concept” (PoC) grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research findings. In 2026, two scientists from the German Cancer Research Center (DKFZ) were once again selected to receive this prestigious funding: Moritz Mall and Chong Sun.

FlareOn Biotech - fluorescence-guided tumour margin detection - 01/07/2026

A sensor designed to visualise residual tumour tissue during surgery

In order to safely remove tumours in the head and neck region, surgeons must be able to reliably distinguish diseased tissue from healthy tissue. FlareOn Biotech, a start-up based in Frickenhausen, has developed a biochemical sensor capable of visualising tumour cells in tissue samples directly in the operating theatre within just ten minutes. The company is now seeking partners to help bring its diagnostic platform to market.

A team led by researchers from the German Cancer Research Center and the HI-STEM* Stem Cell Institute has discovered a new approach to treating advanced colorectal cancer. The study identifies a key marker of particularly aggressive and treatment-resistant colorectal cancer cells. At the same time, the researchers demonstrate using models that already approved drugs targeting this marker can specifically attack the metastasis-initiating cells.

Cancer researcher Dr Alexandra Niedermayer from the Ulm Children’s and Adolescents’ Clinic has been awarded the Franziska Kolb Prize, worth 8,000 euros, by the Ulm University Foundation. The 32-year-old researches aggressive forms of blood cancer and, using modern techniques, has identified an effective, personalised treatment approach.

Certain medicines contain compounds known as PFAS, which are causing increasing environmental harm due to their long-lasting effects. A report by the University of Freiburg, commissioned by the German Environment Agency, shows that many PFAS-based active ingredients used in medicines can be replaced by alternatives. Based on the findings of the report, doctors will in future be able to give preference to prescribing PFAS-free medicines.

For his research on the development of rare malignant tumors in the hereditary DICER1 tumor predisposition syndrome, Dr. Felix Kommoss has been awarded the Rudolf Virchow Prize of the German Society of Pathology. Dr. Kommoss conducts research at the Heidelberg Faculty of Medicine at Heidelberg University and serves as Senior Physician and Head of Gynecologic Pathology at the Institute of Pathology, Heidelberg University Hospital.

The two inter-university funding programs SEED4EU+ and 4EU+ Visiting Professorships are entering a new round of calls. With these programs, the 4EU+ European University Alliance pursues the goal of strengthening links between the eight partner universities, giving scope to new ideas and supporting inter-university projects.

On Thursday, 25 June 2026, several Freiburg cancer researchers were honoured at the presentation of the CRIION Joachim Frank Prize 2026. Among them was Prof. Dr Robert Zeiser, who received the Prize for Biomedical Research. Prof. Dr Jürgen Finke, PD Dr Florian Scherer and PD Dr Elisabeth Schorb of the University Medical Center Freiburg, together with Prof. Dr Gerald Illerhaus of Stuttgart Hospital, were awarded the Prize for Clinical Medicine.

On Thursday, 25 June 2026, several Freiburg cancer researchers were honoured at the presentation of the CRIION Joachim Frank Prize 2026. Among them was Prof. Dr Robert Zeiser, who received the Prize for Biomedical Research. Prof. Dr Jürgen Finke, PD Dr Florian Scherer and PD Dr Elisabeth Schorb of the University Medical Center Freiburg, together with Prof. Dr Gerald Illerhaus of Stuttgart Hospital, were awarded the Prize for Clinical Medicine.

In a virtual reality study involving zebrafish, researchers from the University of Konstanz and King’s College London have discovered that the development of the eye is influenced by what the fish see during the early stages of life – and this, in turn, alters their behaviour.

Four doctoral candidates from Heidelberg University have the opportunity to exchange ideas with outstanding scientists. They are set to take part in the 75th Lindau Nobel Laureate Meeting, which is being held in Lindau from 28 June to 3 July 2026. Jana Braunger, Tim Schubert, Laura Rueda Gensini and Nathan Trausch are among around 600 young researchers who have been selected for their outstanding academic achievements.

The European Research Council (ERC) supports visionary projects in basic research through its “Advanced Grants.” This year, the Council awarded a grant to cancer researcher and physician Dieter Saur from the DKTK Munich* site, and Aurelio Teleman, a metabolism expert at the German Cancer Research Center (DKFZ).

Prof. Dr Fred Hamprecht from the Interdisciplinary Center for Scientific Computing of Heidelberg University is receiving valuable funding from the ERC, which will support a project in the field of computational quantum chemistry. An ERC Advanced Grant also goes to Prof. Dr Andreas Meyer-Lindenberg, Director of the Central Institute of Mental Health and professor at the Medical Faculty Mannheim of Ruperto Carola.

Medical Center – University of Freiburg has created a new miniature animation of the beating heart. To the knowledge of Medical Center – University of Freiburg, it is the first schematic 3D animation to showcase the dynamic movement of the heart in an anatomically and temporally representative manner. It shows that the heart pushes blood into the body while simultaneously drawing blood in from the veins.

In order to further strengthen Heidelberg University as an internationally recognized location of infection research, Prof. Dr Mathias Lichterfeld has been selected for an Alexander von Humboldt Professorship endowed with 7.8 million euros. Leading international academics are granted this most valuable of German research awards to enable them to conduct long-term, cutting-edge research at German universities.

In the latest QS World University Rankings, the University of Freiburg is ranked 14th nationally. It is among the top ten German universities in three indicators. In the overall international ranking, it is ranked 245th out of more than 1,500 other universities.

Gelatin is a versatile natural material. To tailor its properties specifically to the various applications in medicine, diagnostics, and cosmetics, the Fraunhofer IGB has developed a toolbox for chemical functionalization. With the help of automated processes, the modifications can now be scaled under defined conditions, and reproducible batches of modified gelatin can be produced on a scale ranging from grams to kg for customer sampling.

The Collaborative Research Center (SFB) “High Performance Compact Magnetic Resonance” (HyPERiON) has been exploring new avenues in magnetic resonance technology since 2022. Under the leadership of the Karlsruhe Institute of Technology (KIT), the researchers aim to develop high-performance magnetic resonance systems in a benchtop format to make them suitable for widespread use.

It goes without saying that new drug compounds should place as little strain on the heart as possible. But how can potential effects be reliably predicted? Researchers from the NMI, Hannover Medical School (project lead), the Universitat Politecnica de Valencia, and industry partners Multi Channel Systems and Foresee Biosystems are tackling this challenge in the new HEARTCORE project.

The University of Freiburg and Nagoya University are strengthening their strategic partnership through a joint doctoral programme and the Nagoya University Global Campus, which serves as a permanently staffed representative office in Freiburg.

For the first time in 14 years, there has been a change at the top of the hospital rankings, which are published annually by the MINQ Institute in collaboration with Stern. In its very first year of existence, the Heidelberg and Mannheim University Hospitals Consortium has taken first place.

VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, today announced that its previously announced business combination (“Business Combination”) with Voyager Acquisition Corp. (NASDAQ: VACH, “Voyager”), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon Capital Group LLC, was closed successfully (the “Closing”)

NEURA Robotics (“NEURA”), the pioneer in cognitive robotics and creator of the Neuraverse, today announced a landmark Series C financing with a total round size of up to $1.4 billion to accelerate its mission of building the world’s leading Physical AI platform. The financing brings together global leaders across AI, robotics, compute, manufacturing and industrial infrastructure.

This year’s Schering Young Investigator Award has been awarded to Can Aztekin, a Max-Planck-Research Group Leader at the Friedrich Miescher Laboratory of the Max Planck Society in Tübingen, to recognize his significant work in the field of regenerative biology.

Experts in Heidelberg have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections. Using digitized standard stains, the system identifies more than 100 molecular subtypes of central nervous system tumors, delivers results within minutes, and could accelerate the diagnosis of brain tumors worldwide.

Researchers at Heidelberg Faculty of Medicine at Heidelberg University, in collaboration with partners from 29 German study centers, have found evidence of a potential biomarker for personalized therapy of acute myeloid leukemia (AML) in a Phase II study. Analyses showed that certain patients could benefit from additional treatment with the drug Motixafortide in addition to standard chemotherapy.

In response to stress or damage, cells undergo senescence and stop dividing. However, if senescent cells accumulate in tissues over the long term, chronic inflammation occurs and the risk of cancer increases. Researchers at the German Cancer Research Center (DKFZ) have now discovered a previously unknown mechanism by which senescent cells protect themselves from oxidative stress and a specific form of cell death known as ferroptosis.

Quantum sensors for magnetic measurements - 02/06/2026

New insights into muscle physiology – contactless and three-dimensional

Contactless measurement of muscle activity and training effects: using highly sensitive quantum sensors, researchers at the Universities of Tübingen and Stuttgart are setting new standards. This technology has the potential to revolutionise clinical diagnostics and optimise training and neuroscience research.

In rare cases, cancer treatments can cause serious long-term effects. These include so-called secondary leukemias. This form of blood cancer can develop when chemotherapy or radiotherapy damages the genetic material of healthy cells. A research team led by a scientist from Ulm has now discovered a molecular protective mechanism against such genomic damage: a peptide.

Leading scientists are pooling their expertise to further advance research and care for psychotic disorders and to align them more closely with the needs of affected individuals.

The German Research Foundation (DFG) funds continuation of Research Training Group (RTG) 2727 “Checkpoints of Innate Immunity in Cancer and Tissue Damage”, with around €5,8 million.

How can effective treatments for neuropsychiatric disorders be developed without having to accept unwanted side effects? Researchers at the NMI have made an important contribution to this field. In their recent paper, “NMDA receptor subtype differential affinity as a key enabler for precision neuropsychiatry,” they demonstrate how specifically targeting subunits of the NMDA receptor opens up new avenues for safer medications.

The German Chemical Industry Fund (FCI) is supporting the course offering ‘DigiChemJN’ at the Faculty of Chemistry and Pharmacy. DigiChemJN strengthens students’ data literacy by providing them qualifications in data-based research methods, experimental datasets, and artificial intelligence (AI).

Which cellular processes ensure that immune responses are controlled precisely? A new study by the Institute of Cell Biology and Immunology Thurgau (BITG) and the University of Konstanz decodes a decisive signalling pathway.

How do antimetabolite cancer drugs damage the genetic material of malignantly transformed cells and thereby destroy them? How might these drugs be used more precisely, particularly in the treatment of pediatric tumors? A new research group led by Dr. Christopher Carnie, a scientist at the Heidelberg Faculty of Medicine at Heidelberg University, will address these questions.

The German Research Foundation (DFG) is establishing new Collaborative Research Centres and extending existing research networks. Several DZHK sites are also involved. Particular emphasis is being placed on new research approaches to inflammation and thrombosis.

Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now reached the world’s most important pharmaceutical market.

Different types of bone marrow stem cells give rise to blood and immune cells. A team led by Simon Haas now reports in ​“Nature Cell Biology” how that diversity develops. The findings could help improve stem cell therapies, including treatments for blood cancers.

Living systems such as cells rely on membrane pores and channels to transport molecules, exchange signals, and organize biochemical reactions. These functions emerge from dynamic interactions between molecular components. Researchers at the University of Stuttgart have used DNA nanotechnology to develop a synthetic membrane architecture that mimics such interactions.

The life science group Sartorius has opened a new center in Freiburg, Germany, dedicated to the development and production of quality-critical materials for the cell and gene therapy market. In Freiburg, the company manufactures essential components such as cytokines and growth factors used in these novel therapies. With an investment of more than 140 million euros, Sartorius is reaffirming its strategic focus on this emerging business area.

Chronic pain is among the most common and burdensome health conditions worldwide. But which processes in the nervous system cause pain to be “learned” and thus persist long term? And how can insights into the mechanisms underlying chronic pain be translated into new therapeutic approaches? These questions have been at the core of Rohini Kuner’s research for many years.

Cancer prevention with a single jab - 20/05/2026

Therapeutic vaccine against HPV-induced tumours

Persistent infections with human papillomaviruses (HPV) are the primary cause of cervical cancer. Researchers from Heidelberg have developed a promising therapeutic vaccine consisting of immunogenic virus peptides linked to silica nanoparticles, which is currently being investigated in preclinical studies. The vaccine activates specific cytotoxic T cells and is usable regardless of HLA type.

Research jointly led by scientists at the Heidelberg site of the German Center for Lung Research and investigators in Boston at Massachusetts General Hospital and Harvard Medical School identifies a new immunotherapy-based approach for lung fibrosis: reactivating natural killer cell (NK cells) to eliminate senescent fibroblasts, reverse scarring and restore the lung’s ability to heal.

Medical Center – University of Freiburg demonstrates a fundamental therapeutic approach for hereditary immune system defects in a mouse model. The safety profile of genome editing varies significantly depending on the method and cell type.